Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
responsibility‚ Merck is required to be profitable (base). Since the research of development will never be profitable to shareholders Merck should do develop the drug. Based on Merck’s actual value system‚ it wants to be ethical and even be a good corporate citizen. So Merck should conduct the research. Question 8 - If you were the senior executive of Merck‚ what would you do? (Open question) I would make assessment of the potential costs to develop the drug. If the estimated costs are above the acceptable
Premium Social responsibility Corporation Business ethics
Multinational Cost of Capital Capital Structure‚ Risk and the Cost of Capital for Multinational Companies (1713 words) 2015 Table of Contents Introduction 2 Literature Review 2 Capital Structure‚ Risk and the Cost of Capital for Multinational Companies 2 Criticism to the work and the upstream-downstream hypothesis 2 Conclusion 2 References 2 Introduction “Theoretically‚ MNEs should be in a better position than their domestic counterparts to support higher debt ratios because their cash flows
Premium Multinational corporation Corporation Globalization
Developing Human Capital 38:533:634:01 Spring 2013 David Ferio (848) 445-0862 ferio@smlr.rutgers.edu This interactive‚ theoretically anchored‚ and applied course is aimed at understanding the process and practice of developing human capital. It focuses on the strategic development of talent framed within the context of talent leadership. It is anchored in business strategy and views the arena of talent management as a critical means to achieve competitive advantage. As human resource
Premium Human resource management Final examination
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions:
Premium Decision theory Probability theory Decision tree
Date: January 2001 Chapter Title: How Large are Human-Capital Externalities? Evidence from Compulsory-Schooling Laws Chapter Author: Daron Acemoglu‚ Joshua Angrist Chapter URL: http://www.nber.org/chapters/c11054 Chapter pages in book: (p. 9 - 74) and DaronAcemoglu Joshua Angrist MASSACHUSETTS INSTITUTE OF TECHNOLOGY How Human-Capital Externalities? Evidence from Compulsory Schooling Laws Large Are 1. Introduction The effect of human capital on aggregate income is of central importance
Premium Compulsory education College Productivity
Pfizer Inc.’S Cost of Capital and Capital structure - Xiaoyue Shi The costs of capital and capital structures for Pfizer Inc. and its two competitors Merck & Co. Inc. and Johnson & Johnson in the pharmaceutical industry are analyzed in this memo. When calculating the cost of common stock for the three companies‚ three different approaches including Capital Asset Pricing Model (CAPM)‚ Discounted Cash Flow (DCF) and the bond yield plus risk premium are applied (Appendix A). For CAPM approach
Premium Stock market Stock Weighted average cost of capital
Cost of Equity: For the risk-free rate‚ we decided to use the 30-year old Treasury yield‚ which is currently 4.6%. We believe it is important to match the time horizon when comparing financial assets. Given that stocks have essentially an endless time horizon‚ the 30-year Treasury seems a more reasonable asset by which to compare stocks. 1-month Treasury Bills‚ for instance‚ are comparable to safety-deposit boxes‚ which are completely safe‚ but cannot ever yield a return. It’s highly likely that
Premium Generally Accepted Accounting Principles Investment Asset
page 313 – Merck & Vioxx According to The New York Times article‚ “Merck to Pay $950 Million Over Vioxx” by Duff Wilson‚ the following lawsuits have been settled by Merck: Merck has agreed to pay $950 million and has pleaded guilty to a criminal charge over the marketing and sales of the painkiller Vioxx‚ the company and the Justice Department said Tuesday. Merck agreed to pay a $321 million criminal fine and plead guilty to one misdemeanor count of illegally introducing a drug into interstate
Premium Supreme Court of the United States Pearson Education Pearson PLC
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows
Premium Decision tree Arithmetic mean Variance